In the face of the rising energy consumption costs in the biopharmaceutical industry, controlling gas costs has become a key approach for enterprises to cut expenses and boost efficiency. Industry figures indicate that the procurement cost of liquid nitrogen has been growing at an average annual rate of 15% over the past three years. This has spurred many pharmaceutical companies to hasten their shift to PSA (Pressure Swing Adsorption) nitrogen generation technology.

As a globally renowned CDMO enterprise, ASYMCHEM Pharmaceutical Group, with its astute cost management acumen, has forged a close collaboration with Gamma Gas, a technology-frontrunner in the gas equipment field. Together, they are driving the optimization of production costs through technological innovation.The collaboration between ASYMCHEM and Gamma has a long-standing history. Based on their long-term mutual trust, the two parties have continuously explored innovation in gas supply solutions. In October 2023, ASYMCHEM Pharmaceutical Chemistry (Jilin) Co., Ltd. introduced Gamma's V-series ultra-energy-efficient PSA nitrogen generation system (model GNV495 - 600ME). This equipment redefines the industry's energy-saving standards with its outstanding performance: nitrogen purity reaches 99.995%, flow rate is 600 Nm³/h, and the air-nitrogen ratio is as low as 3.8 under standard conditions, fully meeting the stringent requirements for high-purity nitrogen in biopharmaceutical production.

Compared with traditional PSA nitrogen generation equipment, GNV495 - 600ME demonstrates significant technological advantages. Under the same gas supply indicators, this system only requires one 200kW air compressor, replacing the previous nitrogen generation system that needed a 315kW one, reducing the equipment power by 36.5%. Professional calculations show that the operating energy efficiency of this equipment is more than 40% higher than that of conventional models, reducing power consumption by over 1 million kWh per year. Although the initial procurement cost of the equipment is slightly higher, the return on investment (ROI) can be controlled within 0.5 years through the benefits of energy savings, truly achieving the cost-reduction goal of "short-term investment, long-term gain".

This collaboration not only reflects ASYMCHEM's forward-looking cost management strategy but also validates Gamma's technological leadership in the gas equipment field. In the future, the two parties will continue to deepen their cooperation, injecting new impetus into the high-quality development of the biopharmaceutical industry with intelligent and energy-efficient gas solutions.